Administration of growth factors for the treatment of cns disorders
AssigneeThe Regents of the University of California
InventorKrystof S. Bankiewicz
Life of this patent
Estimating the term…
Abstract
A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.
Claims19
1-15. (canceled)
A method of treating a human patient having a central nervous system disease, the method comprising administering to a target brain tissue of said patient a therapeutically effective amount of a pharmaceutical composition comprising a growth factor, wherein
- said growth factor is administered by intermittent convection enhanced delivery (CED) at a rate that counters the tissue clearance rate of said growth factor,
- there is cessation of growth factor delivery during the intermissions between administrations,
- the intermissions between administration of said growth factor are at least about one week, and
- said therapeutically effective amount is an amount effective to increase neurotransmitter turnover in growth factor-responsive neurons of the mammalian CNS.
A method of treating a human patient having a central nervous system disease, the method comprising administering to a target brain tissue of said patient a therapeutically effective amount of a pharmaceutical composition comprising a growth factor, wherein
- said growth factor is administered by intermittent convection enhanced delivery (CED) at a rate that counters the tissue clearance rate of said growth factor,
- there is cessation of growth factor delivery during the intermissions between administrations,
- the intermissions between administration of said growth factor are at least about one week, and
- said therapeutically effective amount is an amount effective to modulate synapse formation by growth factor-responsive neurons of the mammalian CNS.
A method of treating a human patient having a central nervous system disease, the method comprising administering to a target brain tissue of said patient a therapeutically effective amount of a pharmaceutical composition comprising a growth factor, wherein
- said growth factor is administered by intermittent convection enhanced delivery (CED) at a rate that counters the tissue clearance rate of said growth factor,
- there is cessation of growth factor delivery during the intermissions between administrations,
- the intermissions between administration of said growth factor are at least about one week, and
- said therapeutically effective amount is an amount effective to modulate neurite outgrowth by growth factor-responsive neurons of the mammalian CNS.
Dependencies are inferred from the claim text.